EGFR-NSCLC Market to Observe Stunning Growth at a CAGR of 9.6% During the Forecast Period (2025-2034) | DelveInsight ...

J INTS BIO, Inc. announced that research findings on its investigational fourth-generation EGFR tyrosine kinase inhibitor (TKI), JIN-A02, have been published in Clinical Cancer Research, a leading ...

Identifying population-based eGFR distributions may help to identify patients at risk for developing chronic kidney disease earlier, according to study data published in Kidney International. More ...

In unadjusted analysis, rates of DKA among individuals with an eGFR between 30 and 90 mL/min/1.73 m 2 showed no statistical difference compared with those with an eGFR between 90 and 120 mL/min/1.73 m ...

Ivonescimab's BLA acceptance is a milestone for PD-1/VEGF bispecific antibodies in the U.S., potentially transforming second-line NSCLC treatment post-TKI failure. The HARMONi trial showed ivonescimab ...

The FDA has approved Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) as the first and only subcutaneous, chemo-free ...

Older adults living with heart failure with preserved ejection fraction (HFpEF) are frequently labeled as having chronic ...

For years, Nichole Jefferson battled a series of health problems as she juggled a stressful job in the tech industry while raising her daughter. Then, in 2003, she wasn’t feeling well and went to a ...